ESR1 and breast cancer: Immunoblotting analysis of control versus TWEAK-treated TNBC, HER2 and ER-positive BC cell lines validated the similar levels of non-canonical NF-κB activation, without impacting canonical NF-κB, in all cell lines following TWEAK stimulation.